McDonald's just unveiled an $8.5 billion turnaround plan, and the market's response was a 5% single-day drop to its lowest share price since 2022. For long-term investors, that reaction is more interesting than the plan itself -- it has pushed one of the market's steadiest dividend compounders down to a valuation it hasn't seen in years.
The numbers tell a clear story of underperformance. Over the past five years, McDonald's shares are essentially flat, down roughly 3%, while Burger King parent Restaurant Brands has gained 14% and Yum Brands (Taco Bell, KFC, Pizza Hut) is up 13%. The stock now trades at a trailing price-to-earnings ratio near 18.8, well below its 12-month average of about 24 and a discount to its own historical range. The dividend yield has climbed to roughly 3.2%-3.3%, backed by nearly five decades of consecutive annual increases -- a streak McDonald's has maintained through multiple recessions and consumer pullbacks.
The new "Next" initiative commits about $8.5 billion in franchisee assistance through 2036, with $5 billion deployed by the end of this decade, funding new kitchen equipment, restaurant redesigns, AI-driven ordering tools, and expanded hospitality training. New U.S. president Skye Anderson is tasked with reversing slipping guest counts and sagging customer satisfaction scores -- problems that are company-specific rather than purely macro, since rivals have grown through the same soft-consumer environment that McDonald's has not.
Wall Street's skepticism is reasonable: big capital programs don't guarantee returns, and franchisees ultimately have to execute the plan store by store. But that skepticism is precisely why the valuation has compressed. A business generating the cash flow to fund an $8.5 billion multiyear investment while still raising its dividend isn't broken -- it's a mature, moat-protected franchise model working through an operational rough patch. So what for long-term investors: when a nearly 50-year dividend grower trades at a below-average multiple because of a fixable execution problem rather than a structural one, that gap between price and quality is exactly the kind of mispricing patient capital is built to exploit.